Experimental virus injected into tumors shows early promise, but trial on hold
NCT ID NCT05938296
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a modified herpes virus (BS006) that is injected directly into tumors to kill cancer cells and activate the immune system. It involves 29 adults with advanced solid tumors like melanoma or breast cancer. The study is currently suspended, and its main goals are to check safety and find the right dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BS006 (a modified herpes virus designed to infect and kill cancer cells and boost immune response)
What this could lead to
If it works, this could point toward a new treatment option for advanced solid tumors that are hard to treat with standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 29 participants, currently suspended. The main goal is safety, not effectiveness, and many early-stage cancer treatments fail to show benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center
Detroit, Michigan, 48201, United States
-
Orlando Health Cancer Institute
Orlando, Florida, 32806, United States